Prospective randomized study on the multimodal self-treatment of psychogenic erectile dysfunction using a digital health application.

Prospective randomized study on the multimodal self-treatment of psychogenic erectile dysfunction using a digital health application. - ProPED

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036905

Enrollment

Registered

2025-09-16

Start date

2025-12-09

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F52.2

Interventions

Group 1: intervention group (SOC+ multimodal digital therapy of ED) Patients will gain access to the digital therapy Kranus Edera for 12 weeks besides their normal therapeutic established therapy Grou

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Men with psychogenic erectile dysfunction (ICD-10: F52.2) Erectile dysfunction with a total IIEF-5 score of = 21 Age = 18 years Access to a smartphone or tablet Presence of spontaneous nocturnal erections or erections during sexual stimulation Sufficient knowledge of the German language

Exclusion criteria

Exclusion criteria: History of stroke History of myocardial infarction Coronary artery disease (CAD) Peripheral arterial occlusive disease (PAOD) Polyneuropathy Diabetes mellitus Dyslipidemia / lipid metabolism disorder Hyperhomocysteinemia Congenital or acquired penile abnormalities Chronic kidney or liver failure Active cancer Neurogenic diseases (multiple sclerosis, Parkinson's disease, multiple system atrophy, history of spinal cord injury with nerve damage) Hyperthyroidism, hyper- or hypocortisolism Hypogonadism (testosterone deficiency) History of prostatectomy, rectum resection, or other major surgery with nerve damage in the pelvis/retroperitoneum History of pelvic radiotherapy (e.g., for prostate or rectal cancer) History of urethral surgery Obesity (body mass index [BMI] over 30) Nicotine abuse (regular tobacco use) Drug or alcohol dependence Previous participation in Edera therapy Use of medications with erectile dysfunction as a side effect

Design outcomes

Primary

Measure	Time frame
Clinicial relevant improvement of the IIEF-5 score Q0- beginn of study and Q1- after 12 weeks	—

Secondary

Measure	Time frame
QOL-Med ( health-related quality of life) PAM-13 (patient activity) Q0- beginn of study and Q1- after 12 weeks	—

Countries

Germany

Contacts

Public ContactJann-Frederik Cremers

Uniklinikum Münster

jann.cremers@ukmuenster.de+49 251 83-56096

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026